Case Report

A Case of Clostridioides difficile Infection of a Pregnant Woman Treated with Colectomy

Süda Tekin
×Affiliations
  • Department of Infectious Diseases and Clinical Microbiology, Koç University School of Medicine, İstanbul, Turkey
,
Pelin İrkören
×Affiliations
  • Department of Infectious Diseases and Clinical Microbiology, Koç University School of Medicine, İstanbul, Turkey
,
Serkan Sucu
×Affiliations
  • Department of General Surgery, Koç University School of Medicine, İstanbul, Turkey
,
Kinyas Kartal
×Affiliations
  • Department of General Surgery, Yeditepe University School of Medicine, İstanbul, Turkey

Abstract

Clostridioides difficile-associated pseudomembranous colitis (PMC) is a life-threatening inflammatory bowel disease. Here, we aimed to present a 40-year-old woman at 25 weeks of gestation whose pregnancy was terminated earlier than expected. Unfortunately, despite fidaxomicin and oral vancomycin, the patient’s diarrhea did not improve, and she had to undergo a subtotal colectomy. C. difficile infections developing in pregnant women can be catastrophic for both baby and maternal health. Also, antibiotic stewardship is crucial in the prevention of PMC. Therefore, unnecessary and prolonged use of antibiotics should be avoided.

Keywords: Clostridioides difficile, pregnant, colectomy, colitis

Introduction

Clostridioides difficile infections (CDIs) can present in various clinical forms, ranging from an asymptomatic carrier state to pseudomembranous colitis (PMC), and are recognized as one of the leading causes of diarrhea in healthcare centers (1). C. difficile-associated PMC is a life-threatening inflammatory bowel disease and may result in emergency surgical procedures after antibiotic use. Common signs and symptoms of PMC include abdominal pain, diarrhea, nausea, and fever. The diagnosis is possible by detection of C.difficile toxins or genetic material of the bacteria. (2). Recurrence rates of CDIs are reported to be 15–20% and may be as high as 60% after three or more infections, with a mortality rate of 5% (1, 2).

Management of PMC is mostly antibiotic treatment with metronidazole, oral vancomycin, and fidaxomicin. However, in some cases, surgical treatment may be required. The surgical treatment of PMC is generally performed for the life-threatening complications of the disease, such as uncontrolled gastrointestinal bleeding, toxic megacolon, and perforation that develop during medical treatment (3).

Although pregnant women are known as a low-risk group for PMC due to their young age and overall good health, PMC may cause life-threatening problems in pregnant women, and it may be a potential threat to both maternal and fetal health (4). 

Here, we aimed to present a 40-year-old, 25-week pregnant woman whose pregnancy was terminated earlier than expected and who had to undergo subtotal colectomy ten days after caesarean section due to multiple perforations at the colonic segments. 

Case Presentation

Figure 1. The abdominal CT image taken after colon perforation.

A 40-year-old woman, gravida 1, para 0, with 25 weeks of gestation, was admitted to our gynecology and obstetrics department complaining of abdominal pain. In addition, she complained of frequent watery diarrhea episodes (20 bowel movements per day) lasting for three weeks, accompanied by a 10 kg weight loss and dehydration. She was diagnosed with giardiasis because the antigen test for Giardia lamblia resulted in positive at another hospital. She was given ornidazole treatment for ten days, yet her complaints did not resolve. She had also been given a nitrofurantoin treatment with the diagnosis of urinary system infection, although there was no identifying microorganism in the urine culture.

When admitted to the emergency department, she was evaluated by a specialist in infectious diseases and clinical microbiology. Her vital signs included a temperature of 38°C, blood pressure of 110/70 mmHg, and a pulse rate of 80 /minute. The laboratory tests showed leukocytosis with 12,900 white blood cells mm3 and acute phase reactants like C- reactive protein (CRP) level: 70 (N: 0-5) mg/dL and procalcitonin (PCT) level: 0.58 ng/mL were high. Stool culture, microscopic evaluation of stool, and C. difficile toxin A&B are performed immediately. There was no growth in two sets of blood cultures taken when the patient’s fever was high.  SARS-CoV-2 PCR was repeated twice, and the results were negative.

Stool culture was negative for Salmonella spp. and Shigella spp. CDI was defined according to guideline of The Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA); the presence of symptoms (mainly diarrhea) and either a stool test positive for C. difficile toxins or detection of toxigenic C. difficile or colonoscopic or histopathologic findings revealing PMC (5). In our hospital, C. difficile toxin A (TcdA) and toxin B (TcdB) are detected by the VIDAS® method (bioMérieux, Marcy-l’Etoile, France) as part of a two-step algorithm. In the first step, a product of C. difficile, glutamate dehydrogenase (GDH) performed via enzyme-linked immunofluorescence assay (EIA). Then, the detection of C. difficile TcdA and TcdB was performed directly on the stool using premier toxins A and B according to the manufacturer’s instructions. In our case, both GDH and TcdA were positive in the stool with the enzyme-linked fluorescent assay (ELFA) test and by PCR.

She had given oral vancomycin 4×125 mg immediately. However, her diarrhea had not resolved, so her treatment changed to oral fidaxomicin, and she was discharged. 

Four days later, TcdA, checked at the outpatient clinic, tested positive for the second time. She had been hospitalized again because she was dehydrated. Oral fidaxomicin was stopped, and oral vancomycin 4×125 mg and IV metronidazole 4×500 mg were started. On the first day of her second admission, she was taken to the operating room for a cesarean section because of membrane rupture and cervical dilatation. She gave birth to a preterm infant in her 28th week of gestation. Her baby, whose body weight was 1230 gr, was admitted to the neonatal intensive care unit. 

On the third day of her admission, the stool toxin assay for TcdA tested negative. The gastroenterology department consulted the patient, whose diarrhea continued despite toxin negativity, to exclude other accompanying intestinal pathologies. A colonoscopy was performed, considering chronic inflammatory bowel disease as an underlying condition since her diarrhea continued for over three weeks. The flexible sigmoidoscopy was preferred with no air insufflation to avoid perforation of the inflamed colon. In the colonoscopy, widespread diffuse ulcerations and mucosal loss consistent with PMC were seen in all colon segments and rectum. Multiple biopsies were performed. The pathology report was also consistent with pseudomembranous pancolitis and came out negative for cytomegalovirus (CMV) infection. Meantime, CMV DNA PCR was also negative in blood tests. 

On the tenth day of her admission, the patient complained of severe abdominal pain. Her physical examination was remarkable for diffuse rebound tenderness in all four quadrants, consistent with the acute abdomen diagnosis. Her CRP level was 173 mg/L, and her leukocyte count was 11,820 K/uL. Abdominal computed tomography (CT) scan showed free fluid and air consistent with perforation of hollow viscus with pancolitis. The abdominal CT image taken after colon perforation is given in Figure 1. She was urgently taken to the operating room; in the exploratory laparotomy, more than five perforated segments were detected in the colon. Subtotal colectomy with an end-terminal ileostomy was performed. The macroscopy of the colon removed in operation is shown in Figure 2. In pathological examination (acute pancolitis; perforation, multiple small ulcerations, pseudomembranous formation, in some parts showing findings of ischemic and hemorrhagic damage) was evaluated. She was taken to the intensive care unit in the immediate postoperative period, and her meropenem and metronidazole treatment was continued. 

On postoperative day one, the patient was discharged to the surgical ward from the intensive care unit, and she started on a liquid diet and total parenteral nutrition. Her ileostomy started working. Meropenem treatment ceased on postoperative day two, and she started on a solid diet without any problems in toleration. On postoperative day 11, we did not see any problems in oral and intravenous contrast abdominal CT; we ceased oral metronidazole treatment and discharged the patient.  

The patient is still being followed out. Her ileostomy was closed. Her son is 16 weeks old with a body weight of 7520 gr. Both the patient and her son are healthy. 

Discussion 

Figure 2. The macroscopy of the colon.

A 25-week pregnant woman whose pregnancy was terminated early because of PMC due to C. difficile colitis and had to undergo emergent subtotal colectomy is presented here. Although publications emphasized that CDIs pose an increased risk in pregnant women, especially after cesarean section, diagnosis during pregnancy may increase morbidity and mortality of both mother and baby (4, 6). 

The risk factors associated with CDIs include age over 65, female gender, chronic bowel inflammatory diseases, obesity, prolonged hospital admissions, antibiotics disrupting the normal microbiome, and the surgery itself (7). Our case had no risk factors other than antibiotic use for the last two weeks. There was no previous history of antibiotic-associated diarrhea. A study including 2671 pregnant women revealed two risk factors for CDI, cesarean section delivery and the use of antibiotics, especially ampicillin/ gentamicin/clindamycin (8). The increase in the CDIs may also be attributable to the inappropriate use of antibiotics, gastrointestinal flora disorders leading to microbial flora change, and non-compliance with infection control measures, especially hand hygiene, environmental cleaning, and disinfection (1). Different antibiotics were given before the infectious disease diagnosis was clarified in our case. 

C. difficile infections are a major health problem for many countries. According to the results of some studies, a high diversity within RT027-like C. difficile isolates is shown (9, 10).  The rate of antimicrobial-resistant C. difficile isolates is rapidly increasing all around the world. However, Turkey has limited data on this subject (11). Bolukcu et al. showed the changes in epidemiology and incidence of C. difficile infection in our country (12). Another study in Turkey deduced the presence of C. difficile (especially ribotypes 027 and 078) in different meat products (13). 

Clinical findings associated with CDIs can range from asymptomatic carrier stage to life-threatening toxic megacolon. PMC is the most known form of CDIs, characterized by yellow plaques composed of small ulcerations of mucous membranes. Signs and symptoms of PMC include abdominal pain, frequent watery diarrhea, and dehydration (14). Our patient had acute diarrhea with abdominal pain and relevant risk factors, including recent antibiotic use. Laboratory diagnosis of CDI requires demonstrating C. difficile toxin(s) or detecting toxigenic C. difficile organism(s). Nucleic acid amplification tests (NAATs) for the diagnosis alone or initial EIA screening for GDH antigen and toxins A and B is recommended (2). In our patient, C. difficile toxin(s) tested positive in the stool three times with ELFA.  After toxin negativity was detected in the patient, a colonoscopy was performed, considering chronic inflammatory bowel disease as an underlying condition since her diarrhea continued and enteritis lasted longer than three weeks. The flexible sigmoidoscopy was preferred with no air insufflation to avoid perforation of the inflamed colon.

If possible, the first step in managing CDI is to discontinue any precipitating antibiotics (15). Although the use of antibiotics carries a risk for the development of CDI, antibiotics are used in managing and treating these patients. The recommended first-line antimicrobials for the treatment of CDI are oral vancomycin (125 mg 4 times a day for ten days) and oral fidaxomicin (200 mg two times daily for ten days). In patients with recurrent CDI episodes, fidaxomicin is suggested rather than a standard course of vancomycin in the latest guidelines (16). Oral vancomycin was given to our pregnant patient at the first admission, and when there was no clinical regression and the toxin relapsed in the test, she was switched to fidaxomicin. For patients with multiple recurrences or in severe disease with toxic megacolon, characterized by hypotension or shock, ileus oral vancomycin and metronidazole combination treatment is recommended (2). Fecal microbiota transplantation is a promising option in severe patients with fulminant colitis (5).  Despite fidaxomicin, the patient’s diarrhea did not improve. Although it is stated as the first-line treatment in current guidelines, it has been emphasized that the response to fidaxomicin is insufficient in severe and recurrent cases. Although fidaxomicin is offered as the first choice in treatment, it has also been shown to be resistant (16). So oral vancomycin with the combination of metronidazole was given. Meropenem treatment could not be stopped because colon perforation developed in the patient.

Surgical therapy is generally considered in patients with “fulminant” C. difficile colitis who have hypotension or shock, ileus, or megacolon (2). Fulminant C. difficile colitis only occurs in 2 to 3 percent of patients with a CDI but accounts for the most severe CDI complications such as ileus, colonic perforation, and death (17). Our patient had severe abdominal pain and abdominal distension ten days after the cesarean section. Colon perforation was diagnosed with an abdominal CT scan. Since the mortality of patients in this population continues to be high (20-85%), patients should be monitored very closely, and the timing of emergency surgery is critical (18). By following our case closely, we noticed the perforation in the early period.

Subtotal colectomy remains the procedure of choice in fulminant infection, perforation, and colon necrosis (19). Our case was also taken to an emergency operation, and a subtotal colectomy with a terminal end ileostomy was performed. Eight antepartum and six postpartum CDI cases were seen in France between 2008 and 2013. Because pregnant patients have multiple risk factors, including hospitalization, antibiotic use, and comorbidities, they are not in the low-risk group as before (20). 

In our case, CDI was the first attack, and there was no serious underlying problem. However, she could not be managed despite her premature birth and effective medical treatments. After the perforation, she was treated with immediate surgery. 

In conclusion, it should be kept in mind that severe CDIs developing in pregnant women can be catastrophic for both baby and maternal health. Also, antibiotic stewardship is crucial in preventing PMC, so unnecessary and prolonged use of antibiotics should be avoided.

Ethical Approval: N.A.

Informed Consent: Informed consent was obtained from the patient.

Peer-review: Externally peer-reviewed

Author Contributions: Concept – S.T.; Design – S.T.; Supervision – S.T., K.K.; Materials – S.T., K.K.; Data Collection and/or Processing – S.T., P.İ.; Analysis and/or Interpretation – S.T., K.K.; Literature Review – S.T., K.K.; Writer – S.T., S.S., P.İ.; Critical Reviews – S.T.; Other – S.S., P.İ.

Conflict of Interest: The authors declare no conflict of interest.

Financial Disclosure: The authors declared that this study has received no financial support.

Show References

References

  1. Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, et al; Emerging Infections Program Clostridioides difficile Infection Working Group. Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med. 2020;382(14):1320-30. [CrossRef]
  2. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987-94. [CrossRef]
  3. Klingler PJ, Metzger PP, Seelig MH, Pettit PD, Knudsen JM, Alvarez SA. Clostridium difficile infection: risk factors, medical and surgical management. Dig Dis. 2000;18(3):147-60. [CrossRef]
  4. Meda M, Virgincar N, Gentry V, Walker A, Macdonald N, Hooper M, et al. Clostridium difficile infection in pregnant and postpartum women in 2 hospitals and a review of literature. Am J Infect Control. 2019;47(1):e7-e14. [CrossRef]
  5. Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029-44. [CrossRef]
  6. Ruiter LJ, Sophie V, Czuzoj SN, et al. Obstetrical Clostridium difficile infection: a retrospective cohort study. Obstetrics and Gynecology. 2017;129:49.
  7. Sartelli M, Di Bella S, McFarland LV, Khanna S, Furuya-Kanamori L, Abuzeid N, et al. 2019 update of the WSES guidelines for management of Clostridioides (Clostridiumdifficile infection in surgical patients. World J Emerg Surg. 2019;14:8. [CrossRef]
  8. Unger JA, Whimbey E, Gravett MG, Eschenbach DA. The emergence of Clostridium difficile infection among peripartum women: a case-control study of a C. difficile outbreak on an obstetrical service. Infect Dis Obstet Gynecol. 2011;2011:267249. [CrossRef]
  9. Krutova M, Nyc O, Matejkova J, Kuijper EJ, Jalava J, Mentula S. The recognition and characterisation of Finnish Clostridium difficile isolates resembling PCR-ribotype 027. J Microbiol Immunol Infect. 2018;51(3):344-51. [CrossRef]
  10. Tratulyte S, Miciuleviciene J, Kuisiene N. First genotypic characterization of toxigenic Clostridioides difficile in Lithuanian hospitals reveals the prevalence of the hypervirulent ribotype 027/ST1. Eur J Clin Microbiol Infect Dis. 2019;38(10):1953-9. [CrossRef]
  11. Sayın E, Bilgin H, Söyletir G, Ülger Toprak N. [In vitro activities of antimicrobials against toxigenic Clostridioides difficile isolates obtained in a university training and research hospital in Turkey]. Mikrobiyol Bul. 2020;54(3):368-77. Turkish. [CrossRef]
  12. Bolukcu S, Hakyemez IN, Gultepe BS, Okay G, Durdu B, Koc MM, et al. Clostridium difficile infection: Is there a change in the underlying factors? Inflammatory bowel disease and Clostridium difficile. Saudi J Gastroenterol. 2019;25(6):384-9. [CrossRef]
  13. Muratoglu K, Akkaya E, Hampikyan H, Bingol EB, Cetin O, Colak H. Detection, characterization and antibiotic susceptibility of Clostridioides (Clostridium) difficile in meat products. Food Sci Anim Resour. 2020;40(4):578-87. [CrossRef]
  14. Kazanowski M, Smolarek S, Kinnarney F, Grzebieniak Z. Clostridium difficile: epidemiology, diagnostic and therapeutic possibilities-a systematic review. Tech Coloproctol. 2014;18(3):223-32. [CrossRef]
  15. Kelly CP, LaMont JT. Clostridium difficile–more difficult than ever. N Engl J Med. 2008;359(18):1932-40. Erratum in: N Engl J Med. 2010;363(16):1585. [CrossRef]
  16. Sholeh M, Krutova M, Forouzesh M, Mironov S, Sadeghifard N, Molaeipour L, et al. Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2020;9(1):158. [CrossRef]
  17. Hurley BW, Nguyen CC. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med. 2002;162(19):2177-84. [CrossRef]
  18. Sartelli M, Malangoni MA, Abu-Zidan FM, Griffiths EA, Di Bella S, McFarland LV, et al. WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg. 2015;10:38. [CrossRef]
  19. Vely A, Ferrada P. Role of surgery in Clostridium difficile infection. Clin Colon Rectal Surg. 2020;33(2):87-91. [CrossRef]
  20. de Curraize C, Rousseau C, Corvec S, El-Helali N, Fihman V, Barbut F, et al. Variable spectrum of disease and risk factors of peripartum Clostridium difficile infection: report of 14 cases from French hospitals and literature review. Eur J Clin Microbiol Infect Dis. 2018;37(12):2293-9. [CrossRef]